BioTech 365

OCTOBER 28, 2020

–(BUSINESS WIRE)–S2 Genomics, Inc., today announced that it has entered into a distribution agreement with D-Mark Biosciences for the promotion, sales, and support of S2’s Singulator™ 100 System and associated products for single-cell genomics and cell biology applications in … Continue reading →

Genomics 40

Genomics Genome Sales Research 40

BioTech 365

SEPTEMBER 9, 2020

–(BUSINESS WIRE)–S2 Genomics, Inc., LIVERMORE, Calif.–(BUSINESS

Genomics 40

Genomics Genome Sales Production 40

Pharmaceutical Technology

JULY 29, 2022

A nitrogen-binding drug, its global sales were $292m in 2021, as per GlobalData. According to Bumcrot, regRNAs are “RNAs that arise out of the non-coding genome”. Other treatments include sodium phenylbutyrate marketed as Buphenyl or Ammonaps. GlobalData is the parent company of Pharmaceutical Technology.

RNA 245

RNA Gene Expression Gene Gene Therapy 245

Pharmaceutical Technology

OCTOBER 26, 2022

According to GlobalData insight, gene therapies are expected to display the greatest forecasted sales growth, with an increase over 1,200%, while gene-modified cell therapies are expected to show the second greatest forecasted sales growth, with an increase slightly below 1,000%.

Gene Therapy 130

Gene Therapy Gene Marketing Manufacturing 130

Camargo

NOVEMBER 11, 2020

Presumably, Antares’ long-established 90-person urology sales force can achieve pull-thru of this drug product. In November 2017, Foundation Medicine received approval for FoundationOne CDx , a genomic profiling test for solid state tumors, which paved the way for partnerships with pharma companies’ therapeutics.

Development 242

Development Bioequivalency Generic Drugs Production 242

pharmaphorum

JANUARY 24, 2022

The sale also marks a retreat from healthcare for the tech giant, which is remarkable given that it once said it viewed health as second only to financial services market as a market opportunity.

Radiology 111

Radiology Marketing Genome Genomics 111

BioTech 365

JANUARY 9, 2022

NanoString Announces Commercial Leadership Transition NanoString Announces Commercial Leadership Transition Chad Brown to Retire Following More than Four Successful Years as SVP, Sales & Marketing Genomics and Diagnostics Veteran John D.

Genome 40

Genome Genomics Sales Marketing 40

The Pharma Data

AUGUST 27, 2020

FoundationOne Liquid CDx analyses more than 300 cancer-related genes and multiple genomic signatures to help inform treatment decisions for all solid tumour cancers. FoundationOne Liquid CDx adds to Foundation Medicine’s genomic testing portfolio supporting Roche’s mission to deliver truly personalised healthcare.

FDA Approval 52

FDA Approval Genome Genomics Gene 52

The Pharma Data

JANUARY 12, 2021

KSQ is also eligible to receive tiered royalties on net sales of each approved product. sales for that product. KSQ’s proprietary CRISPRomics® discovery engine enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas. and retain royalties on all ex-U.S.

Development 52

Development Research In-Vivo Genome 52

pharmaphorum

JULY 13, 2022

The first subject has now been given a dose of VERVE-101, in what is thought to be the first test in humans of an experimental CRISPR/Cas9 genome editing technique known as base editing. Through base editing, drugs replace single nucleotide in the DNA strand with another, without making double-strand breaks (DSBs) in the gene.

Gene Editing 98

Gene Editing Trials Drugs In-Vivo 98

Pharma Marketing Network

JANUARY 18, 2023

He also has deep experience leading B2B marketing functions for high-growth SaaS and data providers across product marketing, demand creation, sales enablement, and other disciplines. He also attended Singularity University and has an ongoing interest in exponential technologies, including AI, genomics, and nanotech.

Life Science 52

Life Science Marketing Genome Genomics 52

pharmaphorum

DECEMBER 22, 2020

million on the table if certain development, regulatory and sales goals are achieved. Surface could receive up to $730 million in future milestone payments as well as tiered royalties on global net sales. This deal involves an upfront payment of $7 million but there is up to $154.5

Licensing 52

Licensing Licensing Genetics Sales 52

BioSpace

OCTOBER 18, 2022

Editas is reportedly in "advanced discussions" regarding the sale of its preclinical cancer lineup. The company told BioSpace it has undertaken a strategic review to inform opportunities.

Sales 40

Sales Genomics Genome Medicine 40

The Pharma Data

JANUARY 14, 2021

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Containment 52

Containment Genome Genomics Sales 52

pharmaphorum

FEBRUARY 10, 2022

In recent years, concepts including AI-led candidate selection, centralised clinical data monitoring, online sales, and virtual consultations have moved into primetime, all with the promise of making workflows more efficient. We know that digital transformation has the potential to rewrite the boundaries of the possible in medicine.

Life Science 105

Life Science Genome Genomics Research 105

The Pharma Data

JANUARY 6, 2021

Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the pricing of its previously announced underwritten public offering of 4,237,288 shares of its common stock at a price to the public of $29.50 7, 2021 05:00 UTC. LA JOLLA, Calif.–(

Dermatology 40

Dermatology Genome Genomics Production 40

The Pharma Data

DECEMBER 14, 2020

engine along with algorithms tuned to predict BBB permeability played an important role in helping determine which CNS cancers and which genomically-defined subtypes of CNS cancer should be prioritized for development. . We leverage advances in machine learning, genomics, and artificial intelligence by using a proprietary A.I.

Drugs 52

Drugs Genome Genomics DNA 52

The Pharma Data

JANUARY 19, 2021

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Containment 52

Containment Genome Genomics Sales 52

The Pharma Data

DECEMBER 1, 2020

NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced today the pricing of an underwritten public offering of 4,794,521 shares of its common stock at a public offering price of $36.50 CAMBRIDGE, Mass., About Intellia Therapeutics.

In-Vivo 40

In-Vivo Containment Genome Genomics 40

The Pharma Data

NOVEMBER 5, 2021

Roche confirms the outlook for the full year and expects a mid-single-digit sales growth at constant exchange rates. Core EPS growth at constant exchange rates is targeted to be broadly in line with sales growth. In addition, the invitation advertisement will be published in the daily and financial press from Monday, 8 November 2021.

In-Vitro 52

In-Vitro Sales Genome Genomics 52

Delveinsight

DECEMBER 7, 2020

Unlike most other industries, in MedTech, AI is not confined to sales and operations ends of the value chain. In May 2020, Freenome initiated AI-EMERGE, a clinical study for the AI-Genomics blood test has been completed, which collected samples from up to 3,000 patients in the US and Canada.

Protein 56

Protein Insulin Development Hormones 56

pharmaphorum

JULY 5, 2022

Notable highlights include the central role the UK has played in the field of genomics, with over 500 thousand patients now in the biobank, and the recent RECOVERY trial – the world’s largest clinical trial into treatments for Covid-19, with more than 40,000 participants across 185 trial sites in the UK.

Life Science 98

Life Science Medicine Biobanking Research 98

pharmaphorum

JULY 27, 2021

Mike Hobby is a veteran of the UK healthcare sector with over 23 years experience working with organisations, including 13+ years in international sales at Molecular Devices (formerly Genetix).

Compliance 66

Compliance Manufacturing Genome Genomics 66

The Pharma Data

NOVEMBER 10, 2020

Pacific Biosciences will not receive any proceeds from the sale of shares in the offering by the selling stockholder. A shelf registration statement relating to the shares of common stock was filed with the Securities and Exchange Commission (the “SEC”) on November 10, 2020 and became automatically effective upon filing.

Sales 40

Sales Scientist Genome Genomics 40

The Pharma Data

DECEMBER 2, 2020

The issuance and sale of the notes are scheduled to settle on December 7, 2020, subject to customary closing conditions. The issuance and sale of the common stock are scheduled to settle on December 7, 2020, subject to customary closing conditions. (NASDAQ: PROG) today announced the pricing of its offering of $75.0 About Progenity.

Sales 40

Sales In-Vitro Containment Development 40

The Pharma Data

NOVEMBER 14, 2021

In recent years, the company has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights. billion in R&D and posted sales of CHF 58.3 In 2020, Roche invested CHF 12.2 Genentech, in the United States, is a wholly owned member of the Roche Group.

In-Vitro 52

In-Vitro Medicine Genome Genomics 52

pharmaphorum

MAY 18, 2022

Genomics has unlocked entirely new insights to what exactly may cause certain neurological conditions. Beyond epilepsy, there is a range of further neurological disorders that are becoming increasingly well-understood.

Gene Therapy 92

Gene Therapy Gene Genetics Development 92

The Pharma Data

JANUARY 20, 2021

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

Sales 40

Sales Genome Genomics Medicine 40

The Pharma Data

DECEMBER 2, 2020

The issuance and sale of the notes are scheduled to settle on December 7, 2020, subject to customary closing conditions. The completion of the offering of common stock is not contingent on the completion of the offering of the notes, and the completion of the offering of notes is not contingent on the completion of offering of common stock.

In-Vitro 40

In-Vitro Sales Containment Development 40

The Pharma Data

DECEMBER 9, 2020

Hepion will also conduct Fibroscans and examine a multitude of candidate biomarkers of NASH resolution and CRV431 efficacy including Pro-C3, Enhanced Liver Fibrosis (ELF) markers, collagens, matrix metalloproteinases, transcriptomics, liver transaminases, and full-scale lipidomic and genomic signatures.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Genome 40

The Pharma Data

SEPTEMBER 29, 2021

These data reinforce the importance of early comprehensive genomic testing to uncover actionable oncogenic drivers, including NTRK gene fusions, to assist identify patients who are presumably to profit from a targeted treatment approach.”. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros.

Gene 52

Gene Protein Clinical Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 11, 2021

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. About Twist Bioscience Corporation.

Antibody 52

Antibody DNA Containment Manufacturing 52

The Pharma Data

OCTOBER 27, 2021

This Product Design approach within vegetable breeding enables the incorporation of cutting edge technologies including genomics, cell biology, artificial intelligence, robotics, and imaging to better design products for growers and consumers. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros.

Development 40

Development Production Branding Life Science 40

The Pharma Data

DECEMBER 16, 2020

Additionally, Evotec is entitled to tiered, potentially double-digit royalties of the net sales of programmes developed under the partnership. ” ABOUT PANOMICS/PANHUNTER PanOmics involves the innovative use of genomics, transcriptomics, proteomics, and phenotypic data in an integrated fashion.

Protein 40

Protein Bioinformatics Containment Drugs 40

pharmaphorum

OCTOBER 12, 2022

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.

Genomics 105

Genomics Genome Medicine Development 105

The Pharma Data

DECEMBER 12, 2020

AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. More recently, AstraZeneca has increased its efforts in immunology research and the development of medicines for immune-mediated diseases.

Development 75

Development Regulation Medicine Containment 75

The Pharma Data

NOVEMBER 15, 2020

Prior to Celgene, she held leadership roles in marketing, sales and new business development from 2002 to 2011 at Johnson & Johnson. Most recently, she was a senior executive at Celgene Corporation, where she led corporate strategy from 2012 to 2017. Before that, Ms.

Clinical Trials 40

Clinical Trials Clinical Trials Production Trials 40